JP2005507635A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005507635A5 JP2005507635A5 JP2002564963A JP2002564963A JP2005507635A5 JP 2005507635 A5 JP2005507635 A5 JP 2005507635A5 JP 2002564963 A JP2002564963 A JP 2002564963A JP 2002564963 A JP2002564963 A JP 2002564963A JP 2005507635 A5 JP2005507635 A5 JP 2005507635A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- human
- antigen
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims 23
- 108091007433 antigens Proteins 0.000 claims 23
- 102000036639 antigens Human genes 0.000 claims 23
- 101000878602 Homo sapiens Immunoglobulin alpha Fc receptor Proteins 0.000 claims 13
- 102100038005 Immunoglobulin alpha Fc receptor Human genes 0.000 claims 13
- 125000000539 amino acid group Chemical group 0.000 claims 11
- 238000000034 method Methods 0.000 claims 11
- 210000004027 cell Anatomy 0.000 claims 10
- 108700019146 Transgenes Proteins 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 102000001301 EGF receptor Human genes 0.000 claims 7
- 108060006698 EGF receptor Proteins 0.000 claims 7
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 6
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 6
- 230000009261 transgenic effect Effects 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 210000003719 b-lymphocyte Anatomy 0.000 claims 5
- 210000004408 hybridoma Anatomy 0.000 claims 5
- 238000012986 modification Methods 0.000 claims 5
- 230000004048 modification Effects 0.000 claims 5
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 4
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims 4
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims 4
- 102000009109 Fc receptors Human genes 0.000 claims 4
- 108010087819 Fc receptors Proteins 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 3
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 3
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 3
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims 3
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 3
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 claims 3
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 claims 3
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 108010073466 Bombesin Receptors Proteins 0.000 claims 2
- 102000047481 Gastrin-releasing peptide receptors Human genes 0.000 claims 2
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 2
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 2
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 2
- 102000000440 Melanoma-associated antigen Human genes 0.000 claims 2
- 108050008953 Melanoma-associated antigen Proteins 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 102100034256 Mucin-1 Human genes 0.000 claims 2
- 108010063954 Mucins Proteins 0.000 claims 2
- 102000015728 Mucins Human genes 0.000 claims 2
- 230000010261 cell growth Effects 0.000 claims 2
- 230000008021 deposition Effects 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 claims 2
- 238000012737 microarray-based gene expression Methods 0.000 claims 2
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims 2
- 101150047061 tag-72 gene Proteins 0.000 claims 2
- 206010008909 Chronic Hepatitis Diseases 0.000 claims 1
- 206010021263 IgA nephropathy Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 230000002637 immunotoxin Effects 0.000 claims 1
- 229940051026 immunotoxin Drugs 0.000 claims 1
- 239000002596 immunotoxin Substances 0.000 claims 1
- 231100000608 immunotoxin Toxicity 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000006166 lysate Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 244000005700 microbiome Species 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26807501P | 2001-02-12 | 2001-02-12 | |
| US33895601P | 2001-11-05 | 2001-11-05 | |
| PCT/US2002/004024 WO2002064634A2 (en) | 2001-02-12 | 2002-02-11 | Human monoclonal antibodies to fc alpha receptor (cd89) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009187733A Division JP2010004888A (ja) | 2001-02-12 | 2009-08-13 | Ｆｃα受容体（ＣＤ８９）に対するヒトモノクローナル抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005507635A JP2005507635A (ja) | 2005-03-24 |
| JP2005507635A5 true JP2005507635A5 (enExample) | 2005-12-22 |
Family
ID=26952868
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002564963A Pending JP2005507635A (ja) | 2001-02-12 | 2002-02-11 | Ｆｃα受容体（ＣＤ８９）に対するヒトモノクローナル抗体 |
| JP2009187733A Withdrawn JP2010004888A (ja) | 2001-02-12 | 2009-08-13 | Ｆｃα受容体（ＣＤ８９）に対するヒトモノクローナル抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009187733A Withdrawn JP2010004888A (ja) | 2001-02-12 | 2009-08-13 | Ｆｃα受容体（ＣＤ８９）に対するヒトモノクローナル抗体 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7192582B2 (enExample) |
| EP (1) | EP1370588A2 (enExample) |
| JP (2) | JP2005507635A (enExample) |
| KR (1) | KR100890088B1 (enExample) |
| CN (1) | CN1312181C (enExample) |
| AU (1) | AU2002240338C1 (enExample) |
| CA (1) | CA2437814C (enExample) |
| IL (2) | IL157274A0 (enExample) |
| MX (1) | MXPA03007144A (enExample) |
| NZ (1) | NZ527977A (enExample) |
| WO (1) | WO2002064634A2 (enExample) |
| ZA (1) | ZA200305996B (enExample) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7192584B2 (en) * | 1991-03-18 | 2007-03-20 | Centocor, Inc. | Methods of treating psoriasis with anti-TNF antibodies |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| EP1372717A2 (en) * | 2001-03-23 | 2004-01-02 | Aphton Corporation | Combination treatment of pancreatic cancer |
| US20090191232A1 (en) * | 2001-05-04 | 2009-07-30 | Gevas Philip C | Combination therapy for the treatment of tumors |
| KR20040049830A (ko) * | 2001-07-09 | 2004-06-12 | 애프톤 코포레이션 | 간, 폐 및 식도의 암 및 전암 상태의 치료 및 예방 |
| US20060165675A1 (en) * | 2002-08-02 | 2006-07-27 | Richman-Eisenstat Janice Beth | Modulation of mesenchymal cells via iga-receptors |
| EP1608984A2 (en) * | 2003-03-28 | 2005-12-28 | Aphton Corporation | Gastrin hormone immunoassays |
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| EP1570858A1 (en) * | 2004-03-05 | 2005-09-07 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Monovalent ligand of the FCalphaRi receptor as an anti-inflammatory agent |
| EP1730193A2 (en) * | 2004-03-29 | 2006-12-13 | Receptor Biologix, Inc. | Monoclonal antibodies to gastrin hormone |
| EP1794586B1 (en) | 2004-09-22 | 2013-01-30 | Cancer Advances, Inc., | Monoclonal antibodies to progastrin |
| WO2006114115A1 (de) * | 2005-04-26 | 2006-11-02 | Trion Pharma Gmbh | Kombination von antikörpern mit glukokortikoiden zur behandlung von krebs |
| EP2298815B1 (en) | 2005-07-25 | 2015-03-11 | Emergent Product Development Seattle, LLC | B-cell reduction using CD37-specific and CD20-specific binding molecules |
| EP3805269A1 (en) | 2006-06-12 | 2021-04-14 | Aptevo Research and Development LLC | Single-chain multivalent binding proteins with effector function |
| JP5189098B2 (ja) * | 2007-08-23 | 2013-04-24 | 三菱化学メディエンス株式会社 | 非特異反応抑制剤 |
| JP6013733B2 (ja) | 2008-04-11 | 2016-10-25 | エマージェント プロダクト デベロップメント シアトル， エルエルシー | Ｃｄ３７免疫治療薬および二機能性化学療法薬とのその組合せ |
| EP2127666A1 (en) | 2008-05-28 | 2009-12-02 | Drug Discovery Factory B.V. | Method for the treatment or prophylaxis of chronic inflammatory diseases |
| US20130195840A1 (en) * | 2010-01-13 | 2013-08-01 | Robert P. Kimberly | Therapeutics and processes for treatment of immune disorders |
| ES2608475T3 (es) * | 2010-04-13 | 2017-04-11 | Celldex Therapeutics, Inc. | Anticuerpos que se unen a cd27 humana y usos de los mismos |
| US9850296B2 (en) | 2010-08-10 | 2017-12-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| US9517257B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| CN108129554A (zh) | 2010-08-10 | 2018-06-08 | 洛桑聚合联合学院 | 红细胞结合性治疗剂 |
| TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
| EP2465536A1 (en) * | 2010-12-14 | 2012-06-20 | CSL Behring AG | CD89 activation in therapy |
| AU2013216863B2 (en) * | 2012-02-10 | 2018-09-06 | Seagen Inc. | Detection and treatment of CD30+ cancers |
| CN104254542A (zh) | 2012-03-09 | 2014-12-31 | 瑞士杰特贝林生物制品有限公司 | 包含分泌-样免疫球蛋白的组合物 |
| EP2636681A1 (en) | 2012-03-09 | 2013-09-11 | CSL Behring AG | Process for enriching IgA |
| EP2636684A1 (en) | 2012-03-09 | 2013-09-11 | CSL Behring AG | Prevention of infection |
| US10946079B2 (en) | 2014-02-21 | 2021-03-16 | Ecole Polytechnique Federale De Lausanne | Glycotargeting therapeutics |
| US10953101B2 (en) | 2014-02-21 | 2021-03-23 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| US10046056B2 (en) | 2014-02-21 | 2018-08-14 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| ES2874884T3 (es) | 2014-02-21 | 2021-11-05 | Ecole Polytechnique Fed De Lausanne Epfl Epfl Tto | Compuestos terapéuticos dirigidos a la glucosa |
| EP3273991B1 (en) * | 2015-03-25 | 2021-05-19 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Anti-cd89 cytotoxic complex |
| JOP20200312A1 (ar) | 2015-06-26 | 2017-06-16 | Novartis Ag | الأجسام المضادة للعامل xi وطرق الاستخدام |
| UA126278C2 (uk) | 2015-09-21 | 2022-09-14 | Аптево Рісьорч Енд Девелопмент Ллс | Поліпептиди, які зв'язують cd3 |
| TW201802121A (zh) | 2016-05-25 | 2018-01-16 | 諾華公司 | 抗因子XI/XIa抗體之逆轉結合劑及其用途 |
| EP3519823B1 (fr) * | 2016-09-30 | 2021-05-12 | Centre National De La Recherche Scientifique | Marqueurs membranaires |
| US12188935B2 (en) | 2016-09-30 | 2025-01-07 | Centre National De La Recherche Scientifique | Method for the evaluation of antiretroviral therapy (ART) effectiveness in HIV-1 CD4+CD89+ cellular reservoirs |
| JP2020513554A (ja) | 2016-12-07 | 2020-05-14 | プロジェニティ， インコーポレイテッド | 胃腸管の検出方法、装置およびシステム |
| IL267538B2 (en) | 2016-12-23 | 2024-05-01 | Novartis Ag | Antibodies against factor XI and methods for use in preventing, treating, managing or reducing the risk of thromboembolic disorder or stroke in a patient |
| EP4108183A1 (en) | 2017-03-30 | 2022-12-28 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
| CA3066756A1 (en) | 2017-06-15 | 2018-12-20 | Cancer Advances Inc. | Compositions and methods for inducing humoral and cellular immunities against tumors and cancer |
| US12150978B2 (en) | 2017-06-15 | 2024-11-26 | Cancer Advances Inc. | Compositions and methods for preventing tumors and cancer |
| EP3638296A1 (en) | 2017-06-16 | 2020-04-22 | The University Of Chicago | Compositions and methods for inducing immune tolerance |
| KR102324568B1 (ko) | 2017-06-21 | 2021-11-10 | 길리애드 사이언시즈, 인코포레이티드 | HIV gp120 및 CD3을 표적화하는 다중특이적 항체 |
| US20210198374A1 (en) | 2018-04-17 | 2021-07-01 | Celldex Therapeutics, Inc. | Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs |
| US12383617B2 (en) | 2018-05-09 | 2025-08-12 | The University Of Chicago | Compositions and methods concerning immune tolerance |
| WO2019246312A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| WO2019246317A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease or condition in a tissue originating from the endoderm |
| CA3120619A1 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
| EP4309722A3 (en) | 2019-12-13 | 2024-08-07 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| MX2022013085A (es) * | 2020-04-21 | 2023-01-11 | Jjp Biologics Sp Z O O | Anticuerpos cd89 anti-humanos humanizados y usos de los mismos. |
| AU2021357841A1 (en) | 2020-10-08 | 2023-06-15 | Affimed Gmbh | Trispecific binders |
| KR102766045B1 (ko) * | 2020-11-06 | 2025-02-10 | 고려대학교 산학협력단 | Fc 알파 수용체 결합력이 향상된 항체 |
| KR102855679B1 (ko) * | 2020-11-06 | 2025-09-04 | 고려대학교 산학협력단 | Fc 알파 수용체 결합 항체 |
| KR102853685B1 (ko) * | 2020-11-06 | 2025-09-01 | 고려대학교 산학협력단 | Fc 알파 수용체 결합력이 증진된 항체 |
| EP4242233A4 (en) * | 2020-11-06 | 2025-01-15 | Korea University Research and Business Foundation | FC ALPHA RECEPTOR BINDING ANTIBODIES |
| EP4376958A1 (en) | 2021-07-30 | 2024-06-05 | Affimed GmbH | Duplexbodies |
| CN121263441A (zh) | 2023-04-19 | 2026-01-02 | 森特萨制药(英国)有限公司 | 可活化的双特异性抗cd89和抗pd-l1蛋白质及其用途 |
| CN117890576A (zh) * | 2023-12-12 | 2024-04-16 | 深圳市陆为生物技术有限公司 | 一种检测CD89-IgA免疫复合物的试剂、方法及其应用 |
| WO2025218725A1 (zh) * | 2024-04-18 | 2025-10-23 | 徕特康(苏州)生物制药有限公司 | 靶向cd20和cd89的髓细胞衔接子抗体及其用途 |
| WO2026002175A1 (zh) * | 2024-06-27 | 2026-01-02 | 无锡徕特康生物科技有限公司 | 靶向ilt7和cd89的髓细胞衔接子抗体及其用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6018031A (en) * | 1989-10-20 | 2000-01-25 | Trustees Of Dartmouth College | Binding agents specific for IgA receptor |
| ES2132072T3 (es) * | 1989-10-20 | 1999-08-16 | Dartmouth College | Anticuerpo monoclonal especifico para receptor iga. |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5198342A (en) * | 1990-07-05 | 1993-03-30 | Immunex Corporation | DNA encoding IgA Fc receptors |
| DE69127627T2 (de) | 1990-08-29 | 1998-02-19 | Genpharm Int | Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5922845A (en) * | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
| DE60036388D1 (de) | 1999-07-30 | 2007-10-25 | Medarex Inc | Therapeutische verbindungen bestehend aus fc rezeptor bindenden wirkstoffen |
| US7563876B2 (en) | 2000-05-08 | 2009-07-21 | Celldex Therapeutics, Inc. | Human monoclonal antibodies to dendritic cells |
-
2002
- 2002-02-11 US US10/073,644 patent/US7192582B2/en not_active Expired - Fee Related
- 2002-02-11 AU AU2002240338A patent/AU2002240338C1/en not_active Ceased
- 2002-02-11 NZ NZ527977A patent/NZ527977A/en unknown
- 2002-02-11 IL IL15727402A patent/IL157274A0/xx unknown
- 2002-02-11 KR KR1020037010590A patent/KR100890088B1/ko not_active Expired - Fee Related
- 2002-02-11 CA CA002437814A patent/CA2437814C/en not_active Expired - Fee Related
- 2002-02-11 WO PCT/US2002/004024 patent/WO2002064634A2/en not_active Ceased
- 2002-02-11 MX MXPA03007144A patent/MXPA03007144A/es active IP Right Grant
- 2002-02-11 EP EP02706236A patent/EP1370588A2/en not_active Withdrawn
- 2002-02-11 JP JP2002564963A patent/JP2005507635A/ja active Pending
- 2002-02-11 CN CNB028078381A patent/CN1312181C/zh not_active Expired - Fee Related
-
2003
- 2003-08-04 ZA ZA2003/05996A patent/ZA200305996B/en unknown
- 2003-08-06 IL IL157274A patent/IL157274A/en not_active IP Right Cessation
-
2009
- 2009-08-13 JP JP2009187733A patent/JP2010004888A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005507635A5 (enExample) | ||
| US12324842B2 (en) | Compositions and methods for making antibody conjugates | |
| US20230295340A1 (en) | Muc1* antibodies | |
| IL157274A (en) | 89CD monoclonal antibodies of human origin, their segments that bind to antigens, hybridomas and transpectomas that produce them, transgenic cells that express them, couplings of biospecific and multispecific molecules, immunotoxins and preparations containing them, methods for their production and methods for detection | |
| JP7461950B2 (ja) | Ｃｄ３抗体およびその医薬用途 | |
| CN102459346B (zh) | 制造异源多聚体分子的方法 | |
| JP6273219B2 (ja) | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 | |
| EP3353213B1 (en) | Anti-mesothelin antibody and composition comprising the same | |
| JP2003516718A5 (enExample) | ||
| CA2892059C (en) | Bispecific antibody | |
| TWI854953B (zh) | 抗ｃｄ３抗體及含有該抗體的分子、及其製造方法 | |
| CN112851808B (zh) | Igf-1r抗体及其作为定位载体用于治疗癌症的用途 | |
| RU2013142600A (ru) | Белки, связывающие специфический мембранный антиген простаты, и соответствующие композиции и способы | |
| CN112969476B (zh) | 多特异性蛋白分子 | |
| JP2018509907A5 (enExample) | ||
| SI2511301T1 (en) | Human antibodies to ERBB 2 | |
| JP2009297037A5 (enExample) | ||
| RU2017134592A (ru) | Антитела к muc16 и их применение | |
| JP2008520186A (ja) | 哺乳類ｅａｇ１イオンチャネルタンパク質に対する新規の抗体 | |
| ME02842B (me) | Potpuno ljudska antitijela specifična za cadm1 | |
| US20230080842A1 (en) | Tetravalent symmetric bispecific antibodies | |
| WO2021097800A1 (en) | Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof | |
| CN116390953A (zh) | 靶向人密蛋白18.2的抗体及其用途 | |
| WO2022166876A1 (zh) | 特异性识别磷脂酰肌醇蛋白聚糖3的单克隆抗体及其应用 | |
| US20220354962A1 (en) | Rapid production of bispecific antibodies from off-the-shelf iggs with high yield and purity |